Literature DB >> 11068139

Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain.

P Kasa1, H Papp, P Kasa1, I Torok.   

Abstract

In the symptomatic treatment of mild to moderately severe dementia associated with Alzheimer's disease, donepezil (E2020) has been introduced for the inhibition of acetylcholinesterase activity in the human brain. However, there is no morphological evidence as to how this chemical agent affects the acetylcholinesterase-positive structures in the various areas of the human and the rat CNS. This study demonstrates by histochemical means that donepezil exerts a dose-dependent inhibitory effect in vitro on acetylcholinesterase activity. The most sensitive areas were the cortex and the hippocampal formation. Within the different layers of the cortex, the cholinoceptive acetylcholinesterase-positive postsynaptic pyramidal cell bodies were more sensitive than the presynaptic cholinergic axonal processes. In the cortex, the cell body staining was already abolished by even 2 x 10(-8)M donepezil, whereas the axonal staining could be eliminated only by at least 5 x 10(-8)M donepezil. In the hippocampus, the axonal acetylcholinesterase reaction end-product was eliminated by 5 x 10(-7)M donepezil. The most resistant region was the putamen, where the staining intensity was moderately reduced by 1 x 10(-6)M donepezil. In the rat brain, the postsynaptic cholinoceptive and presynaptic cholinergic structures were inhibited by nearly the same dose of donepezil as in the human brain. These histochemical results provide the first morphological evidence that, under in vitro circumstances, donepezil is not a general acetylcholinesterase inhibitor in the CNS, but rather selectively affects the different brain areas and, within these, the cholinoceptive and cholinergic structures. The acetylcholinesterase staining in the nerve fibers (innervating the intracerebral blood vessels of the human brain and the extracerebral blood vessels of the rat brain) and at the neuromuscular junction in the diaphragm and gastrocnemius muscle of rat, was also inhibited dose dependently by donepezil. It is concluded that donepezil may be a valuable tool with which to influence both the pre- and the postsynaptic acetylcholinesterase-positive structures in the human and rat central and peripheral nervous systems.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11068139     DOI: 10.1016/s0306-4522(00)00335-3

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  15 in total

1.  C-terminal fragments of amyloid-beta peptide cause cholinergic axonal degeneration by a toxic effect rather than by physical injury in the nondemented human brain.

Authors:  Peter Kasa; Henrietta Papp; Janos Zombori; Peter Mayer; Frederic Checler
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 2.  A review of clinical treatment considerations of donepezil in severe Alzheimer's disease.

Authors:  Aida Adlimoghaddam; Melanie Neuendorff; Banibrata Roy; Benedict C Albensi
Journal:  CNS Neurosci Ther       Date:  2018-07-29       Impact factor: 5.243

3.  Apium graveolens extract influences mood and cognition in healthy mice.

Authors:  Phetcharat Boonruamkaew; Wanida Sukketsiri; Pharkphoom Panichayupakaranant; Wijittra Kaewnam; Supita Tanasawet; Varomyalin Tipmanee; Pilaiwanwadee Hutamekalin; Pennapa Chonpathompikunlert
Journal:  J Nat Med       Date:  2017-02-15       Impact factor: 2.343

4.  In vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile.

Authors:  Chandran Remya; Kalarickal Vijayan Dileep; Ignatius Tintu; Elessery Jayadevi Variyar; Chittalakkottu Sadasivan
Journal:  J Mol Model       Date:  2012-11-16       Impact factor: 1.810

5.  Free energy landscape for the binding process of Huperzine A to acetylcholinesterase.

Authors:  Fang Bai; Yechun Xu; Jing Chen; Qiufeng Liu; Junfeng Gu; Xicheng Wang; Jianpeng Ma; Honglin Li; José N Onuchic; Hualiang Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-25       Impact factor: 11.205

6.  The Effect of Donepezil on Arousal Threshold and Apnea-Hypopnea Index. A Randomized, Double-Blind, Cross-Over Study.

Authors:  Yanru Li; Robert L Owens; Scott Sands; Jeremy Orr; Walter Moraes; Pamela DeYoung; Erik Smales; Rachel Jen; Atul Malhotra
Journal:  Ann Am Thorac Soc       Date:  2016-11

Review 7.  Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.

Authors:  C Sadowsky; J A Davila Perez; R W Bouchard; I Goodman; S Tekin
Journal:  CNS Neurosci Ther       Date:  2010       Impact factor: 5.243

8.  Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.

Authors:  George T Grossberg
Journal:  Curr Ther Res Clin Exp       Date:  2003-04

9.  On the inhibitory affect of some dementia drugs on DNA polymerase Beta activity.

Authors:  V N Vyjayanti; N S Chary; Kalluri Subba Rao
Journal:  Neurochem Res       Date:  2008-01-10       Impact factor: 3.996

Review 10.  Drug therapy of post-stroke aphasia: a review of current evidence.

Authors:  Marcelo L Berthier; Friedemann Pulvermüller; Guadalupe Dávila; Natalia García Casares; Antonio Gutiérrez
Journal:  Neuropsychol Rev       Date:  2011-08-16       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.